Replies to post #422160 on Amarin Corp Plc (AMRN)

[Tatsumaki]

I didn't ignore it. My position remains that the LR-EtEPA patents clearly cite the exact MND-2119 patented formulation. It's spelled out right in the LR patent as I stated in my post to Zip. It's literally in black and f-ing white text in the LR docs. It may elaborate on the method of action as to why the emulsified product delivers more EPA to the lymph system and patent additional uses for the formulation, but the core technology involved is Emulsified EPA (MND-2119) owned by Mochida, using the same emulsifiers and excipients as listed in the Mochida patent in the ranges identified in the Mochida patent. Amarin will owe Mochida a royalty per the 10-Q as it's a product resulting from the license Amarin bought.